Cryotherapy Treatment of Cutaneous Kaposi Sarcoma in a Patient With B-Cell Chronic Lymphocytic Leukemia

A Case Report and Short Review of the Literature

John Doupis, MD, PhD; Georgios Festas, MD; Konstantinos Tsekouras, MD; Antonios Seretis, MD; Christos Fountzilas, MD, FACP

Disclosures

Wounds. 2022;34(1):E1-E6. 

In This Article

Abstract and Introduction

Abstract

Introduction: Kaposi sarcoma (KS) is a low-grade mesenchymal tumor involving the blood and the lymphatic vessels that primarily effaces the skin and is mediated by human herpesvirus-8 (HHV-8) in more than 90% of patients. There are 4 distinct types of KS. Compared with the classic and AIDS-related variants, chronic lymphocytic leukemia (CLL) associated with KS is a relatively rare clinical condition; thus, only a few cases have been reported.

Case Report: This report presents a case study of an 87-year-old patient with B-cell CLL and cutaneous KS managed with cryotherapy, along with a short review of the literature.

Conclusions: Considering that the method is relatively simple and with few adverse effects, cryotherapy may represent a simple and safe treatment method for cutaneous KS. However, more studies should be conducted to further evaluate the effectiveness of cryotherapy as a promising treatment for cutaneous KS.

Introduction

Kaposi sarcoma (KS), a low-grade mesenchymal tumor involving the blood and the lymphatic vessels, primarily effaces the skin and is mediated by human herpesvirus 8 (HHV-8) in more than 90% of patients.[1–4]

It was first described as multiple idiopathic pigmented hemangiosarcoma in elderly males by Moritz Kaposi at the University of Vienna in 1872.[2] Since then, clinicians have described 4 distinct types of KS. The endemic African form of KS was first described in 1914 and occurs predominantly among black adult men aged 25 to 40 years. In addition, a lymphadenopathic subvariant of the African form affects children at a mean age of 3 years.[3] In the 1970s, the third form of KS was described, mainly in patients who are immunosuppressed. Indeed, immunosuppressant treatment in organ transplant recipients and patients on long-term corticosteroids or other immunosuppressive therapy is associated with increased risk for KS development. Additionally, the development of KS is more likely in patients who are immunosuppressed because of malignancy.[1] Finally, a fourth form, epidemic, has been recognized after the emergence of the HIV infection (AIDS-related KS), being predominantly multicentric, visceral, and disseminated, with a more aggressive behavior in comparison with classic KS.[5]

Chronic lymphocytic leukemia (CLL) associated with KS is a relatively rare clinical condition compared with the classic and AIDS-related variants; thus, only a few cases have been reported.[6–10] Reported is the case of an 87-year-old female with B-cell CLL in whom cutaneous KS developed and was managed with cryotherapy. Signed informed consent was obtained from the patient for publication of this case report and accompanying figures.

processing....